From its base near Cambridge, EMBL-EBI has grown into a global centre for biological data, software and training. Its history is rooted in open science, but its current challenge is larger: helping researchers, healthcare systems and industry use expanding datasets responsibly, reliably and at scale for public benefit.
The European Bioinformatics Institute, widely known as EMBL-EBI, occupies a distinctive place in the modern life sciences economy. Based at the Wellcome Genome Campus in Hinxton, near Cambridge, it is one of six sites of the European Molecular Biology Laboratory, an intergovernmental organisation founded in 1974 to advance molecular biology in Europe. EMBL-EBI itself was established in the 1990s as biology began to change from a laboratory discipline into an information-rich science. DNA sequencing, protein analysis and computational methods were creating volumes of data that individual laboratories could no longer manage alone. The institute’s founding purpose was therefore practical and ambitious: to collect, preserve, organise and share biological data so that scientists everywhere could build on it. That public-service role remains central today. The organisation now maintains one of the world’s most comprehensive collections of freely available molecular data resources, ranging from genomes and protein sequences to gene expression, molecular interactions, disease associations, pathways, samples and ontologies. Its homepage promise, unleashing the potential of big data in biology, is not marketing language so much as a description of a long-term operating model.
Over three decades, EMBL-EBI has become part of the working fabric of global research. Its services include major data resources such as the GWAS Catalog, the International Genome Sample Resource and AlphaFold DB, alongside tools for identifier mapping, data submission, annotation and sequence analysis. These resources are used by academic researchers, pharmaceutical companies, biotechnology firms, healthcare projects and public bodies seeking reliable biological evidence. The institute’s value is not limited to storage. Its teams add meaning through curation, annotation and integration with scientific literature and other databases. In a sector where data quality can determine whether research progresses or stalls, that expert intervention is commercially and scientifically significant. An independent Frontier Economics report cited by EMBL-EBI found that its open data resources deliver multibillion-pound value each year, including estimated productivity gains of more than £11.8 billion across public and private sectors. The same work reported that benefits were 108 times higher than the cost of maintaining the institute’s open data resources. For business readers, the message is clear: dependable shared infrastructure can create value far beyond its own balance sheet.
The challenges facing EMBL-EBI are those facing the wider bioinformatics industry, only at greater scale. Biological data is growing rapidly as sequencing becomes cheaper, imaging improves and international biodiversity and health initiatives expand. At the same time, researchers expect faster access, richer analysis tools and clearer links between datasets. Artificial intelligence adds both opportunity and pressure. High-quality biological datasets managed by EMBL-EBI are essential for training and testing new AI tools for the life sciences, and open data stored at the institute played an important role in the development of AlphaFold, the protein structure prediction system created by Google DeepMind. Yet AI also requires careful governance. Automated annotation, text mining, machine learning and large language models may help curators work at scale, but EMBL-EBI’s emphasis remains on evaluation, provenance and quality control. In health and disease, where data can influence diagnosis, drug discovery and precision medicine, reliability is not optional. In biodiversity, where species data must be preserved for future generations, continuity matters as much as innovation. The institute is therefore balancing speed with stewardship.
That balance is reflected in EMBL-EBI’s data stewardship principles. Its approach is based on openness, long-term resilience and expert added value. The institute supports open science by making databases, code and software freely available whenever possible, with licensing policies that aim to use machine-readable open licences for data resources where appropriate. It also recognises that open access only works if resources remain stable over time. Long-term resilience depends on lifecycle management, continuity of staff and infrastructure, data backup and international delivery partnerships. These are not always visible to end users, but they are essential to research productivity. The institute’s recruitment and culture also support this mission. More than three quarters of its workforce has joined from outside the UK, and it continues to recruit internationally, offering support for relocation and family transition. That global talent base reflects the nature of the work: bioinformatics is international, collaborative and dependent on trust between institutions. For EMBL-EBI, the current era is not simply about holding more data; it is about ensuring that data remains usable, lawful, interoperable and valuable.
EMBL-EBI’s story shows how shared data can become infrastructure for modern life science worldwide research. Its future depends on openness, reliability, and careful stewardship as biological datasets continue expanding rapidly. By combining expert curation with responsible AI, it is strengthening trust in computational biology globally. For businesses and researchers, that trust supports better decisions, partnerships, and long-term innovation across sectors. The institute’s continuing challenge is to preserve access while helping science move faster responsibly worldwide.
